ARC and the FDA will be hosting the 2nd Amyloidosis Forum as a series of virtual meetings focused on Novel Endpoint Development in AL amyloidosis. The first of which will be on Thursday, October 15th, 2020. The first meeting is titled Novel Trial Design in Multi-Systemic Rare Diseases, and will provide an overiew of novel endpoints and analysis used in other rare diseases, the approach of regulators, and challenges and opportunities in AL amyloidosis.
The Amyloidosis Forum is a Public Private Partnership between the Amyloidosis Research Consortium (ARC) and the Food and Drug Administration (FDA). The Amyloidosis Forum is focused on accelerating drug development in AL amyloidosis.
Amyloidosis Forum Agenda